The effects of AD098, AD153 and AD639 on obstructive sleep apnoea (OSA) severity in men and women with moderate-to-severe OSA

There was no significant effect of either drug combinations on reducing OSA severity or improving any of the key physiological causes of OSA. However, duloxetine+oxybutynin did significantly increase the fraction of hypopnoeas to apnoeas compared to placebo (p = 0.02; d = 0.54). In addition, duloxetine+oxybutynin reduced time in REM sleep (p = 0.009; d = 1.03) which was positively associated with a reduction in OSA severity (R2 = 0.62; p = 0.02). In summary - neither drug combination significantly improved OSA severity or modified the key OSA physiological causes of OSA when administered as a single dose to unselected OSA. patients.